Company news
Guardant Health, Inc. (NASDAQ:GH) news
Every Guardant Health, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Guardant Health to Appeal Federal District Court Judgment
August 24, 2026
TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the Universi...
August 24, 2026
Gamehaus Holdings Inc. to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on September 8, 2026
August 20, 2026
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
August 11, 2026
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
July 30, 2026
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their L...
July 28, 2026
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
July 9, 2026
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
June 11, 2026
Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Third Quarter of Fiscal 2026 Ended March 31, 2026
June 8, 2026
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Te...
May 28, 2026
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
May 27, 2026
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
May 20, 2026
Guardant Health : Q1 2026 Earnings Call
May 8, 2026
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
May 7, 2026
Guardant Health Receives FDA Approval for Guardant360(R) CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) f...
May 5, 2026
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for...
May 4, 2026
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commerc...
April 30, 2026
Goosehead Insurance, Inc. Announces First Quarter 2026 Results
April 22, 2026
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
April 16, 2026
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metasta...
March 30, 2026
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data
March 24, 2026
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue...
March 18, 2026
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership
March 16, 2026
Manulife Announces Exclusive Partnership with Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia
March 15, 2026
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and...
March 13, 2026
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Ne...
March 10, 2026
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
March 4, 2026
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield B...
March 3, 2026
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
February 19, 2026
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open
February 12, 2026
Guardant Health to Participate in Upcoming Investor Conferences
February 3, 2026
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Ide...
February 2, 2026
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
January 29, 2026
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients wi...
January 22, 2026
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New ...
January 19, 2026
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 11, 2026
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families
January 8, 2026
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch
January 6, 2026
Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and I...
December 29, 2025
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 29, 2025
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
December 11, 2025
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
December 9, 2025
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Tre...
December 5, 2025
Rafay Systems Helps Shape Guardant Health–Led Consortium Defining Open Standard for AI-Ready Data Access
November 12, 2025
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global...
November 12, 2025
Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring
November 10, 2025
New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response
November 6, 2025
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 6, 2025
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
November 5, 2025
Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering
November 5, 2025